Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings Inc (OBIO) delivers innovative biomedical solutions through strategic partnerships, focusing on cardiovascular therapies like cardiac neuromodulation and drug-coated balloon systems. This page provides investors and medical professionals with essential updates on clinical advancements, regulatory milestones, and collaborative developments.
Access real-time updates on OBIO's pioneering work in BackBeat Cardiac Neuromodulation Therapy and Virtue SAB technology. Our news collection covers partnership expansions with industry leaders, trial result announcements, and financial disclosures critical for evaluating the company's progress in treating hypertension and vascular disease.
Key updates include progress reports on late-stage clinical trials, analysis of strategic risk-sharing partnerships, and manufacturing scale-up initiatives for global commercialization. All content is vetted for accuracy and presented in compliance-conscious format suitable for both institutional investors and healthcare stakeholders.
Bookmark this page for streamlined tracking of OBIO's pipeline developments and partnership-driven growth strategy. For comprehensive insights into biomedical innovation and investment considerations, revisit regularly as new information becomes available.
Orchestra BioMed (Nasdaq: OBIO) announced its Q1 2024 financial results and business updates on May 13, 2024. Highlights include the ongoing BACKBEAT global study on AVIM therapy in collaboration with Medtronic, showing long-term reductions in systolic blood pressure. The company highlighted positive data from various cardiovascular studies and presented future plans, including an R&D day event in June 2024. Financially, the company held $75 million in cash and equivalents, with a net cash outflow of $13.1 million. Revenue decreased to $0.6 million from $1.2 million YoY, while R&D expenses rose to $9.1 million. Net loss widened to $13.5 million, or $0.38 per share, compared to $10.9 million, or $0.40 per share, in Q1 2023.
Orchestra BioMed announced that its AVIM Therapy Global Intellectual Property Estate has reached 110 issued patents worldwide, with 37 in the U.S. and 73 internationally. The patents cover over 1,800 claims related to hypertension treatment. The company is currently studying AVIM therapy in the BACKBEAT global pivotal study with Medtronic. Orchestra BioMed will provide an overview of AVIM therapy and the study on June 11, 2024, at an R&D day in New York City.
Orchestra BioMed, a biomedical company, will host an R&D day in New York on June 11, 2024, to discuss their AVIM therapy program for hypertensive pacemaker patients. Key opinion leaders will present on the program's mechanism of action, clinical evidence, and study design.
FAQ
What is the current stock price of Orchestra BioMed Holdings (OBIO)?
What is the market cap of Orchestra BioMed Holdings (OBIO)?
